XML 168 R111.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details) € in Millions, $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 EUR (€) | Dec. 31, 2023 EUR (€) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 EUR (€)
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | € 24,319 |  | € 21,640 |  |  |  |
Amortization expense(e) |  | (1,749) |  | (1,911) | [1] |  | € (1,804) | [1]
Other intangible assets, ending balance |  | 22,629 |  | 24,319 |  |  | 21,640 |
Gross value |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | 85,313 |  | 81,716 |  |  | 78,865 | [2]
Changes in scope of consolidation | [3] | 1,745 |  | 3,401 |  |  | 464 |
Acquisitions and other increases |  | 1,554 | [4] | 3,112 | [4] |  | 571 |
Disposals and other decreases |  | (1,514) |  | (683) |  |  | (543) |
Currency translation differences |  | 3,331 |  | (1,837) |  |  | 2,533 |
Transfers | [5] | 3 |  | (396) |  |  | (174) |
Increase (decrease) through reclassification, intangible assets other than goodwill | [2] | (9,366) |  |  |  |  |  |
Other intangible assets, ending balance |  | 81,066 |  | 85,313 |  |  | 81,716 |
Accumulated amortization & impairment |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | (60,994) |  | (60,076) |  |  | (57,458) | [2]
Changes in scope of consolidation |  |  |  | 33 | [3] |  | 11 |
Amortization expense(e) |  | (2,200) |  | (2,345) |  |  | (2,196) | [6]
Impairment losses, net of reversals | [7] | (264) |  | (932) |  |  | 454 |
Disposals and other decreases |  | 722 |  | 629 |  |  | 525 |
Currency translation differences |  | (2,134) |  | 1,287 |  |  | (1,591) |
Transfers | [5] | (5) |  | 410 |  |  | 179 |
Increase (decrease) through reclassification, intangible assets other than goodwill | [2] | 6,438 |  |  |  |  |  |
Other intangible assets, ending balance |  | (58,437) |  | (60,994) |  |  | (60,076) |
Acquired R&D |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | 6,038 |  | 6,226 |  |  |  |
Other intangible assets, ending balance |  | 8,369 |  | 6,038 |  |  | 6,226 |
Acquired R&D | Gross value |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | 9,772 |  | 10,354 |  |  | 11,207 | [2]
Changes in scope of consolidation | [3] | 1,745 |  | 113 |  |  | 0 |
Acquisitions and other increases |  | 1,006 | [4] | 1,062 | [4] |  | 277 |
Disposals and other decreases |  | (58) |  | (262) |  |  | (72) |
Currency translation differences |  | 606 |  | (242) |  |  | 518 |
Transfers | [5] | (52) |  | (1,253) |  |  | (1,576) |
Increase (decrease) through reclassification, intangible assets other than goodwill | [2] | (153) |  |  |  |  |  |
Other intangible assets, ending balance |  | 12,866 |  | 9,772 |  |  | 10,354 |
Acquired R&D | Accumulated amortization & impairment |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | (3,734) |  | (4,128) |  |  | (3,477) | [2]
Changes in scope of consolidation |  |  |  | 0 | [3] |  | 0 |
Amortization expense(e) |  | 0 |  | 0 |  |  | 0 | [6]
Impairment losses, net of reversals | [7] | (638) |  | (90) |  |  | (1,107) |
Disposals and other decreases |  | 58 |  | 262 |  |  | 75 |
Currency translation differences |  | (191) |  | 94 |  |  | (7) |
Transfers | [5] | (2) |  | 128 |  |  | 388 |
Increase (decrease) through reclassification, intangible assets other than goodwill | [2] | 10 |  |  |  |  |  |
Other intangible assets, ending balance |  | (4,497) |  | (3,734) |  |  | (4,128) |
Products, trademarks and other rights |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | 17,825 |  | 14,927 |  |  |  |
Other intangible assets, ending balance |  | 13,841 |  | 17,825 |  |  | 14,927 |
Products, trademarks and other rights | Gross value |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | 73,733 |  | 69,579 |  |  | 65,906 | [2]
Changes in scope of consolidation | [3] | 0 |  | 3,287 |  |  | 499 |
Acquisitions and other increases |  | 444 | [4] | 1,970 | [4] |  | 195 |
Disposals and other decreases |  | (1,447) |  | (380) |  |  | (423) |
Currency translation differences |  | 2,708 |  | (1,584) |  |  | 1,994 |
Transfers | [5] | 66 |  | 861 |  |  | 1,408 |
Increase (decrease) through reclassification, intangible assets other than goodwill | [2] | (9,156) |  |  |  |  |  |
Other intangible assets, ending balance |  | 66,348 |  | 73,733 |  |  | 69,579 |
Products, trademarks and other rights | Gross value | Antibodies Collaboration agreement | Teva Pharmaceuticals |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Acquisitions and other increases | $ |  |  |  |  |  | $ 500 |  |
Products, trademarks and other rights | Gross value | Antibodies Collaboration agreement | Janssen Pharmaceuticals, Inc |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Acquisitions and other increases | $ |  |  |  |  |  | $ 175 |  |
Products, trademarks and other rights | Accumulated amortization & impairment |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | (55,908) |  | (54,652) |  |  | (52,744) | [2]
Changes in scope of consolidation |  |  |  | 33 | [3] |  | 0 |
Amortization expense(e) |  | (2,094) |  | (2,225) |  |  | (2,099) | [6]
Impairment losses, net of reversals | [7] | 373 |  | (842) |  |  | 1,561 |
Disposals and other decreases |  | 655 |  | 326 |  |  | 411 |
Currency translation differences |  | (1,928) |  | 1,184 |  |  | (1,567) |
Transfers | [5] | (3) |  | 268 |  |  | (214) |
Increase (decrease) through reclassification, intangible assets other than goodwill | [2] | 6,398 |  |  |  |  |  |
Other intangible assets, ending balance |  | (52,507) |  | (55,908) |  |  | (54,652) |
Products, trademarks and other rights | Accumulated amortization & impairment | IO License and Collaboration agreement |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Amortization expense(e) |  |  |  |  |  |  | (226) |
Software |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | 456 |  | 487 |  |  |  |
Other intangible assets, ending balance |  | 419 |  | 456 |  |  | 487 |
Software | Gross value |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | 1,808 |  | 1,783 |  |  | 1,752 | [2]
Changes in scope of consolidation | [3] | 0 |  | 1 |  |  | (35) |
Acquisitions and other increases |  | 104 | [4] | 80 | [4] |  | 99 |
Disposals and other decreases |  | (9) |  | (41) |  |  | (48) |
Currency translation differences |  | 17 |  | (11) |  |  | 21 |
Transfers | [5] | (11) |  | (4) |  |  | (6) |
Increase (decrease) through reclassification, intangible assets other than goodwill | [2] | (57) |  |  |  |  |  |
Other intangible assets, ending balance |  | 1,852 |  | 1,808 |  |  | 1,783 |
Software | Accumulated amortization & impairment |  |  |  |  |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |  |  |  |  |
Other intangible assets, beginning balance |  | (1,352) |  | (1,296) |  |  | (1,237) | [2]
Changes in scope of consolidation |  |  |  | 0 | [3] |  | 11 |
Amortization expense(e) |  | (106) |  | (120) |  |  | (97) | [6]
Impairment losses, net of reversals | [7] | 1 |  | 0 |  |  | 0 |
Disposals and other decreases |  | 9 |  | 41 |  |  | 39 |
Currency translation differences |  | (15) |  | 9 |  |  | (17) |
Transfers | [5] | 0 |  | 14 |  |  | 5 |
Increase (decrease) through reclassification, intangible assets other than goodwill | [2] | 30 |  |  |  |  |  |
Other intangible assets, ending balance |  | € (1,433) |  | € (1,352) |  |  | € (1,296) |
[1] | Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] | (a)Comprises the other intangible assets of Opella, now reclassified to Assets held for sale at December 31, 2024 in accordance with IFRS 5 (see note D.1.).
[3] | (c)The “Changes in scope of consolidation” line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Note D.1.)
[4] | (f)This line mainly comprises: In 2023: –the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus (nirsevimab) (see Note C.2.); –an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co- commercialization of TEV’574;and –an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli. In 2024: –an upfront payment of $500 million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and –an upfront payment of $300 million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and commercialization rights to aficamten in China.
[5] | (b)The “Transfers” line mainly comprises (i) acquired R&D that came into commercial use during the period and (ii) reclassifications of assets (other than Opella assets) as Assets held for sale.
[6] | (e)The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of €226 million in 2022 (see Note C.1.)
[7] | (d)See Note D.5.

X
- Definition The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -Clause vi -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Impairment loss recognised in other comprehensive income; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iii&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -Clause vii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 119 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_OtherIntangibleAssets
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Change In Scope Of Consolidation Through Business Combination, Intangible Assets + References No definition available. + Details
Name: | sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase (decrease) through reclassification, intangible assets other than goodwill + References No definition available. + Details
Name: | sny_IncreaseDecreaseThroughReclassificationIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredRDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsTrademarksAndOtherRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_TevaPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_IOLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |